{"filing":{"accession_number":"0001171843-26-005754","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"f6k_082626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326005754/f6k_082626.htm"},"events":[{"id":29844,"run_id":27339,"accession_number":"0001171843-26-005754","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Optimi Health entered into an equity line of credit (ELOC) with Seven Knots, LLC on August 13, 2026, granting the Company the right to sell up to US$100 million of common shares over the facility's term. The Company also issued convertible promissory notes (US$1.5 million initially, potentially US$500,000 more) convertible into common shares at 95% of the 20-day VWAP with a US$3.00 floor. This is a dilutive equity issuance arrangement that provides the Company with capital-raising flexibility while creating significant shareholder dilution risk, particularly given the convertible notes' favorable conversion terms and the ELOC's discretionary draw structure.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-08-26","form":"6-K","submitted_at":null,"items":[{"id":32257,"accession_number":"0001171843-26-005754","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Optimi Health entered into an equity line of credit (ELOC) with Seven Knots, LLC on August 13, 2026, granting the Company the right to sell up to US$100 million of common shares over the facility's term. The Company also issued convertible promissory notes (US$1.5 million initially, potentially US$500,000 more) convertible into common shares at 95% of the 20-day VWAP with a US$3.00 floor. This is a dilutive equity issuance arrangement that provides the Company with capital-raising flexibility while creating significant shareholder dilution risk, particularly given the convertible notes' favorable conversion terms and the ELOC's discretionary draw structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:05:49.594395+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32257,"accession_number":"0001171843-26-005754","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Optimi Health entered into an equity line of credit (ELOC) with Seven Knots, LLC on August 13, 2026, granting the Company the right to sell up to US$100 million of common shares over the facility's term. The Company also issued convertible promissory notes (US$1.5 million initially, potentially US$500,000 more) convertible into common shares at 95% of the 20-day VWAP with a US$3.00 floor. This is a dilutive equity issuance arrangement that provides the Company with capital-raising flexibility while creating significant shareholder dilution risk, particularly given the convertible notes' favorable conversion terms and the ELOC's discretionary draw structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:05:49.594395+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-08-26"}]}